Pacific Edge Ltd (nzse:PEB) Share Price

Company Profile

Business description
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
Contact
87 Saint David Street
P.O. Box 56
DunedinSTL9016
NZL
T: +64 35776733
https://www.pacificedgedx.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
Employees
34

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,093.37	158.69	0.69%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%